Charts GI Innovation, Inc.

Stocks

End-of-day quote Korea S.E. 06/10/2026			5-day change	1st Jan Change
9,070.00 ^KRW	+2.83%		+13.80%	-48.58%

24/04	GI Innovation Enters Melanoma First-Line Treatment Market with GI-102 Approval for Phase 2 Clinical Trial Direct Comparison with Keytruda	CI
20/03	GI Innovation And Johnson & Johnson Enter Clinical Supply Agreement For Prostate Cancer Combination Therapy	CI

Korea S.E.KRW

Markets		Quality
Korea S.E.	A358570	End-of-day quote

ProRealTime Chart